![Page 1: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/1.jpg)
Barriers to Participation in Clinical Trials Pediatric Oncology
![Page 2: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/2.jpg)
Jeana Cromer, MPH, CCRP
Director, Clinical Trials Management
Oncology Programs
St. Jude Children's Research Hospital
Comprehensive Cancer Center
![Page 3: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/3.jpg)
Agenda
• Childhood Cancer – Overview
• Regulations and Legislation for Pediatric Research
• Ethics of Pediatric Research
![Page 4: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/4.jpg)
Overview of Childhood Cancer
![Page 5: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/5.jpg)
Background
• 1 million diagnosed with cancer annually in the USA
• <1% Childhood cancers• 170,000 lung cancer per year• 175,000 breast cancer per year• 179,000 prostate cancer per year• 10,000 – 12,000 pediatric cancer patients
per yearRef: Hirschfield, et al JCO 2003. Vol 21 pp1066-1073
![Page 6: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/6.jpg)
Childhood Cancer Facts
• In 2007, approximately 10,400 children diagnosed with cancer
• Approximately 1,545 will die from disease
• Leading cause of death by disease in children 1-14 years
American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society. Retrieved December 26, 2007, from http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf.
![Page 7: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/7.jpg)
Childhood Cancer Incidence and Survival Rates
• 11.5 cases per 100,000 children in 1975• 14.8 cases per 100,000 children in 2004• 5-year survival rates for all cancers
combined 58.1% (1975 -1977) to 79.6% (1996-2003)– Significant advances in treatment and
supportive care– Clinical trials research
SEER Cancer Statistics Review, 1975-2004
![Page 8: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/8.jpg)
Common Types of Childhood Cancer
• Leukemias - ALL and AML• Cancers of the central nervous system – Brain tumors• Neuroblastoma• Sarcomas – osteosarcoma, Ewings, soft tissue• Lymphomas – Hodgkin’s lymphoma, non-Hodgkin’s
lymphoma• Liver Cancers – hepatocelluar, hepatoblastoma• Kidney tumors – Wilms, clear cell sarcoma• Retinoblastoma• Germ Cell Tumors• Other Rare Tumors – melanoma, adrenocortical,
nasopharyngeal carcinoma
![Page 9: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/9.jpg)
Childhood Cancer Incidence
• Incidence of childhood cancer peaks in the first year of life
• Incidence is higher for children under 5 years of age and ages 15-19
Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. Nol 99-4649. Bethesda, MD, 1999
![Page 10: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/10.jpg)
Incidence Varies by Type and Age
• The types of cancer in young children under 5 years (neuroblastoma, Wilms, retinoblastoma, hepatoblastoma, ependymoma) are very uncommon in adolescents (years 15-19)
• Cancers common in adolescents (germ cell tumors, lymphomas, bone cancers) are rarely diagnosed in younger children
• Cancers most commonly diagnosed in adults (lung, breast, colon) rarely occur in adolescents or children
Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. Nol 99-4649.
Bethesda, MD, 1999
![Page 11: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/11.jpg)
Regulations and Legislation
![Page 12: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/12.jpg)
Regulatory Approvals (FDA-CDER) 1979-2004
• >100 drugs approved for cancer treatment
• 50 new molecular entities (NME) approved for adult cancers
• Only 7 NME submissions for pediatric oncology– 2 approved (teniposide and clofarabine)
Ref: Hirschfield, et al JCO 2003. Vol 21 pp1066-1073
![Page 13: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/13.jpg)
Key Challenges for Pediatric Drug Development
• Historical Lack of Pediatric Labeling– Tragedies in children led to regulations– “Therapeutic Orphans” Children are not “mini-
adults” or “little adults”• Small Pediatric Market – limited marketing potential• Difficult Trials
– Small #s, difficult outcome measures, need for formulation development (smaller doses, oral formulations)
• Ethical and Liability Issues
![Page 14: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/14.jpg)
Key Challenges for Pediatric Drug Development
• Differences between disease in adult vs pediatric (pathophysiology, PK, organ maturity, etc)– Cannot always extrapolate from adult data
• Differences in pediatric age groups– Need to ensure representation from relevant age
groups in studies• Challenges with procedures/sampling: blood
volumes, diagnostic vs research procedures• Formulations – smaller doses, oral formulations• Ethical considerations: consent, assent,
permission
![Page 15: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/15.jpg)
General Principles: ICH E-11
• Pediatric patients should be given medicines that have been properly evaluated for their use in the intended population
• Product development programs should include pediatric studies when pediatric use is anticipated
• Pediatric development should not delay adult studies nor adult availability
• Shared responsibility among companies, regulatory authorities, health professionals, and society as a whole
![Page 16: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/16.jpg)
Pediatric Goals
• Provide adequate product information for drugs and biologics that will be used to treat children
• Establishment of mechanisms for the safe and effective development of pediatric medications
![Page 17: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/17.jpg)
FDA Principles
• Adequate labeling• Safety• Efficacy
![Page 18: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/18.jpg)
History of Pediatric Regulations/Legislation
• FDAMA Pediatric Exclusivity -1997• Pediatric Rule Regulation -1998• Best Pharmaceuticals for Children Act
(BPCA) - 2002• Pediatric Research Equity Act (PREA) -
2003• October 2007: reauthorization of BPCA
and PREA
![Page 19: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/19.jpg)
What Have We Learned
• For many products studied:– There was new dosing information, or– It was not effective, or– It had a new pediatric safety issue– Long term safety and effects on growth,
learning, and behavior continue to be understudied
– Neonates still remain mostly unstudied as to the safety and efficacy of the therapies being used to treat them.
![Page 20: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/20.jpg)
Ethics of Pediatric Research
![Page 21: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/21.jpg)
Challenges for Pediatric Oncology Drug Development
• Most children with cancer enrolled on clinical trials but– Very small patient populations– Studies may be difficult to enroll,
long time to complete
Impact of Treating Childhood Cancer: Lives Saved
![Page 22: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/22.jpg)
Why Involve Children in Research?
• Develop treatment for childhood diseases– Retinopathy of prematurity– Cystic fibrosis– Cancer
• Data in adults may not be generalizable– May result in over/under dosage of medications– Pathophysiology may be different– Toxicities may be different
![Page 23: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/23.jpg)
Why Involve Children in Research?
• Consequences of not involving children is research:– Perpetuation of harmful practices– Introduction of untested practices– Failure to develop new treatments for
childhood diseases
The Pediatric Gap: New Yorker, 1/10/05
http://www.newyorker.com/archive/2005
![Page 24: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/24.jpg)
Regulatory Framework: Pediatric Research
• HHS conducted or supported research– Domestic* – International
• 45 CFR 46– Subpart A (“Common
Rule”)– Subpart B (Fetus, Pregnant
Women)– Subpart C (Prisoners)– Subpart D (Children)
• Research that involves products regulated by FDA
• 21 CFR 50, 56– Part 50: Protection of
Human Subjects• Subpart D (Children)
Interim Rule– Part 56: IRBs
• 21 CFR 312 – INDs• 21 CFR 361 – Drugs used in
research
Regulatory Protection of Human Subjects:
OHRP FDAApplies to:
*Domestic institutions may elect to apply 45 CFR 46 to all of its research regardless of source of support
![Page 25: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/25.jpg)
Risk Benefit Categories for IRB Consideration of Pediatric Studies
Increasing Risk
Minimal Risk Greater than minimal risk
Special
Decreasing Prospect of Benefit
Prospect of direct benefit
Section 404 Section 405 Section 407 No direct
benefit Section 404 Section 406
Code of Federal Regulations Title 45 Part 46 Subpart D and FDA 50.
![Page 26: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/26.jpg)
Issues in Pediatric Research
• Designation as “vulnerable” adds a layer of protection as well as denying access
• Children lack legal capacity to consent• Many are incapable of understanding research• Pediatric trials are more difficult to complete
![Page 27: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/27.jpg)
Pediatric Ethics
• BENEFICIENCE• RESPECT FOR PERSONS• JUSTICE
![Page 28: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/28.jpg)
Principals of Medical Ethics
• Respect for person is dominant principle for adult ethics (autonomy)
• Beneficence is dominant principle for pediatric ethics (best interests of child)
![Page 29: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/29.jpg)
Questions in Pediatric Ethics
• Should a particular therapy be given?– BENEFICIENCE
• Who should make a consent decision?– AUTONOMY
The answers may be incompatible
![Page 30: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/30.jpg)
Consent, Assent, and Permission
• Consent– An adult’s voluntary agreement, based upon
adequate knowledge and understanding of relevant information/legal capacity/sufficient understanding
• Assent– A child’s affirmative agreement
• Permission– A parent’s or guardian’s agreement
![Page 31: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/31.jpg)
Limits of Parental Authority
• Bests Interests of the Child– reasonable range of options– not always separable from family
interests
• Parental Incompetence• Neglect or Abuse
![Page 32: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/32.jpg)
Informed Consent vs Parental Permission
Autonomous authorization of adults on their own behalf is more robust than parental permission for children by proxy/surrogate
“…the pediatrician’s responsibility to his or her patient exist independent of parental desires or proxy consent.”
AAP 1995 statement on informed consent, parental permission, and assent in pediatric practice
![Page 33: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/33.jpg)
Purposes of Assent
• Provide information to the young person• Offer shared decision making with the
parents• Honor the young person’s dissent
![Page 34: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/34.jpg)
Assent: A Clinical Definition
• Awareness of the nature of his/her condition
• What to expect with tests and treatment(s)• Assessment of understanding (including
pressure to accept)• Soliciting an expression of willingness to
accept the proposed test/treatment
![Page 35: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/35.jpg)
Authority of Assent
• Therapeutic studies with direct benefit available only in the context of research: NO
• Therapeutic studies with no direct benefit: YES
• Non-therapeutic studies: YES
![Page 36: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/36.jpg)
Key Concepts for Children to Understand about Research Participation
1. What is required of them
2. Duration of their participation
3. Personal risks and benefits
4. Voluntariness
5. Freedom to ask questions
![Page 37: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/37.jpg)
Assent/Parental Permission*
• The IRB must determine that adequate provisions are made for soliciting the assent of children when in the judgment of the IRB the children are capable of providing it:– Age/Maturity– Intellectual development– Psychological, emotional state
*21 CFR 50.55, 45CFR46.408
![Page 38: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/38.jpg)
Assent/Parental Permission*
• The assent of the child is not a necessary condition for proceeding with the clinical investigation if:– The capability of some or all of the children is
so limited that they cannot be reasonably be consulted
– The intervention or procedure holds out a prospect of direct benefit that is important to the health or well-being of the children and is available only in the context of the clinical investigation
*21 CFR 50.55, 45CFR46.408
![Page 39: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/39.jpg)
Pediatric Research: Emerging Issues
• Consent at age of majority• Genetic research
– Family studies (secondary subjects)
– Non-CLIA approved tests (do we share results?, e.g. MRD)
![Page 40: Barriers to Participation in Clinical Trials Pediatric Oncology](https://reader035.vdocuments.net/reader035/viewer/2022062619/5515628655034691418b4b5e/html5/thumbnails/40.jpg)